title: CKD-mineral and bone disorder management in kidney transplant recipients.
abstract: Kidney transplantation, the most effective treatment for the metabolic abnormalities of chronic kidney disease (CKD), only partially corrects CKD-mineral and bone disorders. Posttransplantation bone disease, one of the major complications of kidney transplantation, is characterized by accelerated loss of bone mineral density and increased risk of fractures and osteonecrosis. The pathogenesis of posttransplantation bone disease is multifactorial and includes the persistent manifestations of pretransplantation CKD-mineral and bone disorder, peritransplantation changes in the fibroblast growth factor 23-parathyroid hormone-vitamin D axis, metabolic perturbations such as persistent hypophosphatemia and hypercalcemia, and the effects of immunosuppressive therapies. Posttransplantation fractures occur more commonly at peripheral than central sites. Although there is significant loss of bone density after transplantation, the evidence linking posttransplantation bone loss and subsequent fracture risk is circumstantial. Presently, there are no prospective clinical trials that define the optimal therapy for posttransplantation bone disease. Combined pharmacologic therapy that targets multiple components of the disordered pathways has been used. Although bisphosphonate or calcitriol therapy can preserve bone mineral density after transplantation, there is no evidence that these agents decrease fracture risk. Moreover, bisphosphonates pose potential risks for adynamic bone disease.
authors.affiliation: Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL, USA.
authors.forename: Hala M
authors.initials: HM
authors.lastname: Alshayeb
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Josephson
authors.forename: Stuart M
authors.initials: SM
authors.lastname: Sprague
mesh_terms: D000368:Aged; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008903:Minerals / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000601:surgery*
chemical_list: D008903:Minerals